Nusrat Islam Chaity is a third-year PhD student in the Drug Discovery Biology program at the Monash Institute of Pharmaceutical Sciences (MIPS), working in the Metabolic Receptor Biology laboratory. She is supervised by Dr Peishen (Elva) Zhao and Professor Denise Wootten. Her PhD research focuses on the pharmacological characterization of incretin hormone receptors polymorphisms associated with metabolic disorders, including type 2 diabetes and obesity.

Dr. Lu is a Full Professor in University of Macau. He received his Ph.D. degree in Shanghai Institute of Meteria Medica, Chinese Academy of Sciences in 2009. Currently, he is mainly engaged in the discovery and mechanism study of anti-cancer compounds based on tumor microenvironment. He is also interested in studying the new targets and strategies for cancer therapy. Dr. Lu has published more than 200 scientific papers in the SCI journals including J Hematol Oncol, Adv Sci, Acta Pharm Sin B and Pharmacol Ther (Total citations 13000+, H-index 60, Scopus). He is the Director of the Editorial Office and Associate Editor of Chinese Medicine. Dr. Lu was awarded as the 2nd Prize of Natural Science: Macao Science and Technology Awards (twice) and CNPHARS Annual Young Pharmacologists.

Miss Irina Lotsaris is an emerging pharmacologist completing her PhD at the University of Sydney. Miss Lotsaris’ research focusses on using in vitro techniques to characterise and develop drugs for membrane proteins, with an emphasis on drug discovery and characterisation of the solute carrier 6 transporter family. This project ties in her bachelor’s degree, where she majored in medicinal chemistry and neuroscience at the University of Sydney, with a first-class honours in pharmacology. She has attended major international-level conferences including the 2025 Biomolecular Horizons conference and the 2026 Gordon Research Conference for membrane transporter proteins and has won numerous awards for different projects encompassed in her PhD. Miss Lotsaris is often commended on her enthusiastic and captivating presentations, inspiring great discussions in drug design and development, and promising insights into the use of combined in silico and in vitro approaches in the pharmacology field.

Wenjuan Ma, PhD, is an Associate Chief Pharmacist at the Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, China. She holds a Bachelor of Pharmacy from Shandong University, Master's degree from Sun Yat-sen University, and doctorate from China Pharmaceutical University, with postdoctoral training at the Affiliated Drum Tower Hospital of Nanjing Medical University. Specializing in nephrology and rheumatology/immunology, Dr. Ma focuses on translational immunopharmacology for autoimmune diseases, particularly systemic lupus erythematosus, with expertise in individualized therapeutics, therapeutic drug monitoring, and the development of novel antibody, peptide, and cell-based therapeutic strategies. Her work has been published in journals including ACS Nano, Advanced Science and Molecular Pharmaceutics. As Principal Investigator, she has led multiple competitive projects including the National Natural Science Foundation of China Young Scientists Fund and major provincial programs in Fujian.

Dr. Yujing Wu, M.D., Ph.D., is an Associate Professor and Master's Supervisor at Anhui Medical University. Her expertise lies in anti-inflammatory immune pharmacology and clinical pharmacology. Her research rigorously investigates the pathological mechanisms of IgD in Rheumatoid Arthritis (RA) and hematologic diseases, alongside the pharmacodynamics and molecular mechanisms of IgD-Fc-Ig fusion proteins. Dr. Wu has led projects funded by the National Natural Science Foundation of China and provincial programs. She has authored over 40 SCI publications. She holds three Chinese invention patents and has received a Provincial Third Prize in Natural Science. Her presentation details the identification of the FcδR complex as a novel target in RA therapy.